Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 16/20 | 0.42 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638727 | 0.91 | CCR1 (0.47) | CXCR3CCR1SMO | |
| SCHEMBL1638728 | 0.91 | CCR1 (0.47) | CXCR3CCR1SMO | |
| SCHEMBL12765598 | 0.90 | CXCR3 (0.43) | CXCR3CCR1KCNH2 | |
| SCHEMBL13658231 | 0.88 | CXCR3 (0.42) | CXCR3CCR1KCNH2 | |
| SCHEMBL13456282 | 0.88 | CCR1 (0.56) | CXCR3CCR1KCNH2 | |
| SCHEMBL13658199 | 0.88 | CXCR3 (0.41) | CXCR3CCR1SMOKCNH2 | |
| SCHEMBL12765594 | 0.86 | CXCR3 (0.43) | CXCR3CCR1 | |
| SCHEMBL12726222 | 0.85 | CXCR3 (0.43) | CXCR3CCR1SMO | |
| SCHEMBL13658133 | 0.83 | CXCR3 (0.51) | CXCR3CCR1KCNH2 | |
| SCHEMBL1639324 | 0.82 | CCR1 (0.48) | CXCR3CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CXCR3 15/4885CCR1 1/4885SMO 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.